// App-Quantinova.ai

204 : Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)

Researchers

Presenter

  • F. Eskandary

Principal Investigators

  • H. Regele

  • G. Bond

  • N. Kozakowski

  • M. Wahrmann

  • L. Hidalgo

  • H. Haslacher

  • C. Kaltenecker

  • M-.B. Aretin

  • R. Oberbauer

  • J. Reeve

  • P. Halloran

  • G. Bohmig

Medical Centers

  • Nephrology and Dialysis, Medical University Vienna, Vienna, Austria

  • Institute of Neurology, Medical University of Vienna, Vienna, Austria

  • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada

  • Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria

  • Pharmacy Department, General Hospital Vienna, Vienna, Austria

  • Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada

Locations

  • Austria

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved